(Sharecast News) - The Financial Mail on Sunday's Midas column spied long-term potential in Destiny Pharma's shares.
Focusing on MRSA, other post-operative infections and those chronically ill after taking antibiotics, the company's products had the potential to generate annual sales of over £2bn.

While still in development, some were being...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE